POM-V Prescription Required

Protivity Lyophilisate and Solvent for Suspension for Injection for Cattle

Active ingredient: Mycoplasma bovis

Form

Injection

Species

Cattle

Manufacturer

Zoetis Belgium S.A.

VMD MA No.

60021/3092

What it's used for

Onset of immunity: 12 days after the basic vaccination scheme. Duration of immunity: has not been established.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Mycoplasma bovis

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Protivity Lyophilisate and Solvent for Suspension for Injection for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Onset of immunity: 12 days after the basic vaccination scheme.
Duration of immunity: has not been established.

Reconstitute the lyophilisate with the solvent to obtain a suspension for injection.
After reconstitution, the suspension should be pinkish to orange-brown turbid in color.
Basic vaccination scheme:
Two doses, each of 2 ml, should be administered 3 weeks apart to calves from 1 week
of age. The second dose should preferably be administered on the alternate side of
the neck.

None.

Cattle:
Very common
(>1 animal / 10 animals treated):
injection site swelling
Common
(1 to 10 animals / 100 animals
treated):
injection site pain
injection site warmth
injection site nodule
Uncommon
(1 to 10 animals / 1,000 animals
treated):
lameness
More than 5 cm in diameter observed on the day of vaccine administration and
resolving spontaneously within 3 days.
On the day of vaccine administration.
Less than 0.8 cm
in volume observed from 10 days after vaccination and lasting
between 1 to 5 days.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder <or its local representative> or the national
competent authority via the national reporting system. See also section “Contact
details” of the package leaflet for respective contact details.

Vaccinate healthy animals only.
The potential impact of maternally derived antibodies on efficacy of vaccination has
not been established.
The product is a live attenuated vaccine. Antimicrobials active against Mycoplasma
spp. should not be given 15 days before or after vaccination or during the two-dose
basic vaccination scheme as they could interfere with vaccine efficacy. Within these
time frames, and in the situation where a clinical condition requires the prescription of
antimicrobials, preference should be given to those with no anti-Mycoplasma spp.
activity.

Special precautions for safe use in the target species:
The safety of the veterinary medicinal product has not been established in breeding
bulls.
The live attenuated Mycoplasma bovis vaccine strain may disseminate into synovial
fluid, lymph node, middle ear, conjunctiva, tonsil and lung tissue after vaccination.
In a laboratory study conducted using a dose 7-fold higher than the maximum
bacterial content, nasal shedding was observed for at least 9 days post-vaccination in
an animal vaccinated through intramuscular and subcutaneous routes. However, the
vaccine strain did not spread to in-contact control animals.
Distinguishing between field strains and the vaccine strain of M. bovis can be
performed by whole genome sequencing tests. Additional information to differentiate
the vaccine strain from field strains is available upon request from the marketing
authorisation holder.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
No special precautions to be taken by the person administering the veterinary
medicinal product to animals are necessary as M. bovis is not considered to present
a risk to healthy humans. However, in case of development of adverse reactions
following accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.

Store and transport refrigerated (2 C – 8 C).
Keep the vial in the outer carton in order to protect from light.

Zero days.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.